Mark Hillman Hillman Capital Management
Mark Hillman is associated with Hillman Capital Management, a firm focused on fundamental equity research and long-term portfolio management. The firm’s public filings are followed by investors interested in actively managed, research-driven U.S. equity exposure. Hillman’s process emphasizes business analysis and valuation discipline rather than short-term trading.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$7.47M |
| 2 |
Warner Bros
WBD
|
+$4.68M |
| 3 |
Salesforce
CRM
|
+$1.49M |
| 4 |
BNY
Bank of New York Mellon
BNY
|
+$1.41M |
| 5 |
Microsoft
MSFT
|
+$1.14M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$9.91M |
| 2 |
MMP
Magellan Midstream Partners, L.P.
MMP
|
+$7.38M |
| 3 |
Becton Dickinson
BDX
|
+$129K |
| 4 |
Merck
MRK
|
+$123K |
| 5 |
CVS Health
CVS
|
+$16.9K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 18.33% |
| 2 | Technology | 16.2% |
| 3 | Consumer Staples | 13.92% |
| 4 | Communication Services | 13.79% |
| 5 | Financials | 10.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Alphabet (Google) Class A
GOOGL
$4.22T
| $6.62M | 2.4% |
60,720
+240
| +0.4% | +$28.3K |
|
|
BNY
27
Bank of New York Mellon
BNY
$108B
| $6.38M | 2.32% |
152,965
+31,551
| +26% | +$1.41M |
|
28
Meta Platforms (Facebook)
META
$1.4T
| $6.34M | 2.3% |
39,327
+4,950
| +14% | +$955K |
|
29
T. Rowe Price
TROW
$23.8B
| $6.29M | 2.29% |
55,386
+360
| +0.7% | +$45.8K |
|
30
Zimmer Biomet
ZBH
$19.3B
| $6.15M | 2.23% |
58,508
+6,207
| +12% | +$736K |
|
31
Western Union
WU
$2.28B
| $6.02M | 2.19% |
365,653
+1,984
| +0.5% | +$35K |
|
32
Adobe
ADBE
$109B
| $5.97M | 2.17% |
16,303
+124
| +0.8% | +$50.5K |
|
33
Emerson Electric
EMR
$87.7B
| $5.77M | 2.1% |
72,518
+507
| +0.7% | +$44.7K |
|
|
JWN
34
DELISTED
Nordstrom
JWN
| $5.71M | 2.08% |
270,421
+1,053
| +0.4% | +$26.9K |
|
35
Compass Minerals
CMP
$1.09B
| $5.59M | 2.03% |
157,946
+5,359
| +4% | +$265K |
|
36
Equifax
EFX
$22.6B
| $2.43M | 0.88% |
13,299
+415
| +3% | +$83.1K |
|
37
iShares MSCI EAFE ETF
EFA
$80B
| $1.37M | 0.5% |
21,983
+923
| +4% | +$62.8K |
|
38
Constellation Brands
STZ
$23.2B
| $625K | 0.23% |
2,680
+100
| +4% | +$24.3K |
|
39
Medtronic
MDT
$119B
| $611K | 0.22% |
6,803
+420
| +7% | +$42.6K |
|
40
Air Products & Chemicals
APD
$67.9B
| $592K | 0.22% |
2,463
+174
| +8% | +$42.3K |
|
41
CarMax
KMX
$8.82B
| $572K | 0.21% |
+6,323
| New | +$595K |
|
42
ServiceNow
NOW
$133B
| $546K | 0.2% |
5,745
+730
| +15% | +$69.6K |
|
43
Blackrock
BLK
$179B
| $505K | 0.18% |
830
+67
| +9% | +$43.6K |
|
44
Comcast
CMCSA
$95.3B
| $462K | 0.17% |
11,780
+980
| +9% | +$42K |
|
45
3M
MMM
$92.3B
| $458K | 0.17% |
4,229
+306
| +8% | +$37K |
|
46
GE Aerospace
GE
$361B
| $432K | 0.16% |
10,895
+1,602
| +17% | +$77.6K |
|
|
47
Alphabet (Google) Class C
GOOG
$4.18T
| $234K | 0.09% |
2,140
+180
| +9% | +$21.3K |
|
48
iShares Russell Mid-Cap ETF
IWR
$57.7B
| $168K | 0.06% |
2,602
+32
| +1% | +$2.28K |
|
|
49
Bristol-Myers Squibb
BMY
$137B
| – | – |
-135,731
| Closed | -$9.91M |
|
|
MMP
50
DELISTED
Magellan Midstream Partners, L.P.
MMP
| – | – |
-150,465
| Closed | -$7.38M |
|
Similar funds
Mark Hillman's Q2 2022 Portfolio in Review
As of Q2 2022, Mark Hillman held 50 positions worth $275M, down 13% from $315M the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Mark Hillman's Q2 2022 filing shows 2 new, 43 increased, 3 reduced and 2 closed positions. Its largest new stake was Lam Research: 156,880 shares worth $6.69M. The largest sale was Bristol-Myers Squibb, an estimated $9.91M.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, down from 20% a quarter earlier, followed by Technology and Consumer Staples.
- Mark Hillman's largest Q2 2022 buy was Lam Research: 156,880 shares worth $6.69M.
- Mark Hillman added most to Warner Bros in Q2 2022, an estimated $4.68M increase.
- Mark Hillman's biggest Q2 2022 reduction was Becton Dickinson, cutting an estimated $129K.
- Mark Hillman fully exited Bristol-Myers Squibb in Q2 2022, selling an estimated $9.91M.
- Mark Hillman's ten largest holdings make up 35% of its $275M portfolio in Q2 2022.
- Mark Hillman opened 2 new positions and closed 2 in Q2 2022.
- Mark Hillman's portfolio value fell 13% quarter-over-quarter to $275M.
Based on Hillman Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.